Biotech Values

[mcbio]

ARQL

This is based on the conjecture that the futility analysis was a real one and the claims by the co that c-Met+ group had "substantial" (stat significant?) in Met+ subgroup and for cMet- HR<~1.1. ("no difference").

Sorry, I went back and checked the prior presentation and I believe the reference was only to "substantial improvement" and not also to "stat sig." So, presumably results were not stat sig or they would have said so but let's wait to see the actual data at ESMO.

Separately, ARQL is working on BTK inhibitors now. Does anyone see any ways in which a follow-on BTK can improve upon ibrutinib or otherwise is there room for a second drug similar to ibrutinib (e.g., compete on cost)? Most seem to agree that ibrutinib is going to be a very big-selling drug.